Genelux Corporation
NASDAQ:GNLX · NASDAQ Global Market
+$0.08 today
Vol 0.10M · Avg 0.19M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:GNLX · Revenue to Net Income
Key Ratios
Analysis
$8.0K of revenue converted into -$31.8M of net income for the selected period. Gross margin is -437.5% and net margin is -28896.9%, showing how much revenue survives after costs and taxes. EPS is $-0.88, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0K +0.0% | $8.0K -95.3% | $170.0K -98.5% | $11.1M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $574.0K -36.4% | $903.0K -11.3% | $1.0M +5.2% | $968.0K +8.2% | $895.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$566.0K +36.8% | -$895.0K -5.5% | -$848.0K -108.4% | $10.1M +1228.5% | -$895.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | -7075.0% +4112.5pp | -11187.5% -10688.7pp | -498.8% -590.1pp | 91.3% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $19.9M +4.5% | $19.0M +48.8% | $12.8M +40.6% | $9.1M +43.7% | $6.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $13.4M +5.2% | $12.7M +9.8% | $11.6M +131.2% | $5.0M -39.7% | $8.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $32.6M +6.0% | $30.8M +32.1% | $23.3M +77.8% | $13.1M -4.4% | $13.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $574.0K -36.4% | $903.0K -11.3% | $1.0M +5.2% | $968.0K +8.2% | $895.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$31.6M -9.0% | -$29.0M -9.5% | -$26.5M -1428.4% | -$1.7M +87.3% | -$13.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -394637.5% -32562.5pp | -362075.0% -346512.1pp | -15562.9% -15547.3pp | -15.6% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$33.2M -4.8% | -$31.7M -31.2% | -$24.2M -702.0% | -$3.0M +79.4% | -$14.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -415175.0% -18975.0pp | -396200.0% -381985.3pp | -14214.7% -14187.5pp | -27.2% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M -26.6% | $1.5M +497.1% | $244.0K | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $4.0M +182.2% | $1.4M -22.4% | $1.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.1M -41.5% | $1.8M +144.2% | -$4.1M -277.7% | -$1.1M +38.0% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$32.1M -7.6% | -$29.9M -5.6% | -$28.3M -589.0% | -$4.1M +74.9% | -$16.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -401812.5% -28450.0pp | -373362.5% -356717.2pp | -16645.3% -16608.2pp | -37.1% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 -100.0% | $1.1M | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$32.1M -7.6% | -$29.9M -5.6% | -$28.3M -443.4% | -$5.2M +70.7% | -$17.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -401812.5% -28450.0pp | -373362.5% -356717.2pp | -16645.3% -16598.2pp | -47.0% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +9.5% | -$1 +18.1% | -$1 -452.4% | -$0 +69.6% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +9.5% | -$1 +18.1% | -$1 -452.4% | -$0 +69.6% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $37.2M +18.2% | $31.5M +28.7% | $24.4M -0.5% | $24.6M +4.0% | $23.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $37.2M +18.2% | $31.5M +28.7% | $24.4M -0.5% | $24.6M +4.0% | $23.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$853.58M
Candel Therapeutics, Inc.
NASDAQ:CADL
$449.08M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$391.08M
Silence Therapeutics plc
NASDAQ:SLN
$321.19M
Cellectis S.A.
NASDAQ:CLLS
$308.78M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.31M
AC Immune S.A.
NASDAQ:ACIU
$242.73M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$114.01M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.71M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GNLX generate?
Genelux Corporation (GNLX) reported $8,000.00 of revenue in fiscal 2025.
Is GNLX profitable?
Genelux Corporation (GNLX) reported -$32,145,000.00 of net income, with a net margin of -401812.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.